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Abstract
Background: Recent studies suggested that induction of epithelial-mesenchymal transition (EMT) might confer both
metastatic and self-renewal properties to breast tumor cells resulting in drug resistance and tumor recurrence. TGFb is a
potent inducer of EMT and has been shown to promote tumor progression in various breast cancer cell and animal models.
Principal Findings: We report that chemotherapeutic drug doxorubicin activates TGFb signaling in human and murine
breast cancer cells. Doxorubicin induced EMT, promoted invasion and enhanced generation of cells with stem cell
phenotype in murine 4T1 breast cancer cells in vitro, which were significantly inhibited by a TGFb type I receptor kinase
inhibitor (TbRI-KI). We investigated the potential synergistic anti-tumor activity of TbR1-KI in combination with doxorubicin
in animal models of metastatic breast cancer. Combination of Doxorubicin and TbRI-KI enhanced the efficacy of doxorubicin
in reducing tumor growth and lung metastasis in the 4T1 orthotopic xenograft model in comparison to single treatments.
Doxorubicin treatment alone enhanced metastasis to lung in the human breast cancer MDA-MB-231 orthotopic xenograft
model and metastasis to bone in the 4T1 orthotopic xenograft model, which was significantly blocked when TbR1-KI was
administered in combination with doxorubicin.
Conclusions: These observations suggest that the adverse activation of TGFb pathway by chemotherapeutics in the cancer
cells together with elevated TGFb levels in tumor microenvironment may lead to EMT and generation of cancer stem cells
resulting in the resistance to the chemotherapy. Our results indicate that the combination treatment of doxorubicin with a
TGFb inhibitor has the potential to reduce the dose and consequently the toxic side-effects of doxorubicin, and improve its
efficacy in the inhibition of breast cancer growth and metastasis.
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Introduction
Breast cancer is the leading cause of cancer death in women
with more than a million newly diagnosed cases annually
worldwide [1]. It is estimated that 30–75% of patients undergoing
surgery and adjuvant treatment will develop recurrent metastatic
disease. Metastatic breast cancer (MBC) is essentially incurable
with standard therapy and patients with MBC have a median
survival of about 2 years after metastasis have been detected [2].
Doxorubicin is an anthracycline drug widely used in chemother-
apy regimen for patients with MBC [3] and shown overall
response rates of between 35 and 50% in patients with MBC who
have not previously received chemotherapy [4]. Despite its
excellent anti-tumor activity, doxorubicin has a relatively low
therapeutic index and its clinical utility is limited due to acute and
chronic toxicities such as myelosuppression, immunosuppression
and dose-cumulative cardiotoxicity [5]. Therefore, combination
treatment with another highly effective novel non-toxic drug
which can lower the dose of chemotherapeutic agents would be
desirable.
Transforming growth factor beta (TGFb) has been shown to be
overly produced during progression of various types of carcinomas
including breast cancer [6,7] and to accelerate metastatic
progression [8–10]. Several mechanisms are believed to mediate
TGFb’s tumor-promoting activity. TGFb produced by tumor cells
can act in a paracrine fashion to stimulate myofibroblast
differentiation [11] and tumor angiogenesis [12], and to suppress
host immune surveillance [13]. Acting in an autocrine fashion,
TGFb signaling has been shown to be necessary for the survival of
breast cancer cells [14,15] and to induce epithelial-mesenchymal
transition (EMT) and cell migration [16]. Due to its oncogenic
role, various components of TGFb pathway are being evaluated as
therapeutic targets [17–19]. TGFb type I receptor (TbRI) kinase is
one potential target for the blockade of TGFb signaling [20].
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10365Several studies showed that treatment with TbRI kinase inhibitors
(TbRI-KI) can inhibit malignant properties of cancer cells in vitro
and in vivo [21–25].
Recent studies have demonstrated that EMT induced by TGFb
and other factors is associated with the expression of many stem
cell markers and phenotypes in transformed human mammary
epithelial cells [26,27]. These studies suggest that TGFb-induced
EMT may result in the maintenance and formation of stem-like
breast cancer cells. This notion is consistent with a recent report
demonstrating an enhanced TGFb isoform expression and
pathway activity in CD44+ breast cancer cells [28]. Although
TGFb-associated drug resistance has been described previously
[29], these recent findings would suggest that TGFb-induced drug
resistance may be in a large part due to its induction of stem-like
features in carcinoma cells. Thus, TGFb inhibitors should
potentiate the efficacy of chemotherapeutic agents, especially for
those agents that can adversely activate TGFb pathway.
It was found that various anti-tumor drugs induced TGFb1
production in tumor cells [29,30], which could increase the
potential of recurrent disease. In our study, we observed that
chemotherapeutic drug doxorubicin activates TGFb signaling in
human breast cancer MDA-MB-231 and murine breast cancer
4T1 cells. Doxorubicin induced EMT, promoted invasion and
enhanced generation of cells with stem cell phenotype in murine
4T1 breast cancer cell line in vitro, which were significantly
inhibited by TbRI-KI. Our in vivo studies showed for the first
time the benefit of simultaneous treatment of doxorubicin with a
TGFb antagonist to improve the inhibition of tumor growth and
lung/bone metastasis in a syngeneic immunocompetent murine
xenograft model and in a nude mice xenograft model of human
breast cancer.
Results
Doxorubicin stimulated both motility and invasion of
murine and human breast cancer cells
Cell motility and invasion are integral processes in the
metastatic dissemination of tumor cells. Doxorubicin has been
used for the treatment of metastatic breast cancer. Therefore, we
tested the effect of doxorubicin on the migration and invasion of
murine 4T1 and human MDA-MB-231 cells in a Boyden chamber
assay. Surprisingly, instead of inhibition, treatment with doxoru-
bicin significantly enhanced both 4T1 and MDA-MB-231 tumor
cell migration (Figure 1A and Figure 1B). Enhanced invasion
through matrigel was also observed with both 4T1 and MDA-MB-
231 cells after treatment with doxorubicin (Figure S1A and Figure
S1B respectively). As expected, TGFb1 treatment significantly
induced both motility and invasion in both cell lines under similar
conditions. These results indicated that doxorubicin could act like
TGFb and might have the potential to promote tumor metastasis
by stimulating tumor cell motility and invasion.
Doxorubicin enhanced TGFb signaling in murine and
human breast cancer cells
Doxorubicin has been shown to induce circulating TGFb and
lung metastasis in xenograft and transgenic animal models [31,32].
To examine whether activation of TGFb signaling has any role in
the doxorubicin induced migration/invasion, we examined the
effect of doxorubicin treatment on TGFb-mediated phosphoryla-
tion of Smad2 and Smad3 in both murine 4T1 and human MDA-
MB-231 cells. After treatment for 6 days, we found that similar to
TGFb1 treatment (2 ng/ml), doxorubicin treatment (25 nM) also
stimulated phosphorylation of Smad2 and Smad3 proteins in both
4T1 and MDA-MB-231 (Figure 2) cells, which was inhibited by
the addition of the TGFb inhibitor TbRI-KI. Similar results were
also obtained during a shorter duration of treatments (24 hours)
with TGFb3 or doxorubicin in the presence or absence of TbRI-
KI (Figure S2A). Like TGFb1, doxorubicin could also induce the
transcriptional activation of a TGFb-responsive PAI-1 promoter in
a dose-dependent manner (Figure S2B). Thus, our results indicate
that doxorubicin can activate the TGFb pathway, which can be
antagonized by a kinase inhibitor of TbRI in both breast cancer
cell lines in vitro.
TbRI-KI reversed Doxorubicin- or TGFb-induced EMT
Acquisition of mesenchymal phenotype through EMT has been
shown to be associated with aggressive breast cancer subtypes and
Figure 1. Stimulation of migration by doxorubicin and TGFb treatment in murine and human breast cancer cells. In a Boyden Chamber
migration assay, 40,000 murine breast cancer 4T1 cells (A) and human breast cancer MDA-MB-231 cells (B) in serum free medium were placed inside
the insert of an invasive chamber and treated with doxorubicin (100 nM) or TGFb1 (5 ng/ml in A and 1 ng/ml in B) for 6 hours (4T1 cells) and
24 hours (MDA-MB-231 cells). Lower chamber contained the medium with 1% serum as chemoattractant. Cells were removed from the upper surface
of the chamber membrane and the membrane was then stained for the migratory cells, which were counted under a microscope. Results are the
mean of the five fields of observation at 1006magnification and expressed as mean+SEM. ‘‘*’’ indicates significant difference from the control value
with ANOVA test, P,0.05.
doi:10.1371/journal.pone.0010365.g001
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potent inducer of EMT. It induces EMT not only during
embryonic development but also during tumor progression in
vivo [34]. An essential role for TGFb mediated Smad signaling has
been demonstrated in EMT associated with tumor metastasis [35].
Therefore, we investigated whether the TGFb- or doxorubicin-
induced EMT phenotype can be reversed by the treatment with
the TbRI-KI. Due to the spindle shaped morphology of the
human breast cancer MBA-MB-231 cells, the detection of
additional EMT was difficult. F-actin staining of the cytoskeleton
could detect a small number of MDA-MB-231 cells with an
enhanced mesenchymal phenotype which was abrogated by the
addition of TbRI-KI (Figure S3A and S3B). To study the effect of
TbRI-KI on the EMT generated by doxorubicin, therefore we
have focused on murine 4T1 cells with an epithelial morphology.
The treatment of murine 4T1 cells with TGFb1 (2 ng/ml) and
doxorubicin (25 nM) for 7 days generated majority of the cells
with mesenchymal spindle-shaped morphology (Figure 3A).
Vimentin, which is a marker associated with mesenchymal
morphology, showed increased expression after TGFb1 treatment
and was significantly reduced by the addition of TbRI-KI
(Figure 3B). However, the level of vimentin expression was not
increased after doxorubicin treatment (data not shown) suggesting
that doxorubicin may activate other pathways in addition to the
TGFb pathway to regulate vimentin expression. EMT was evident
after treatment with TGFb1 or doxorubicin as detected by
polarized organization of the actin cytoskeleton (Figure 3C). We
also observed an increased nuclear translocation of the transcrip-
tion factor Snail, which is known to promote EMT [36] after the
treatment of the 4T1 cells with TGFb1 or doxorubicin (Figure 3C).
The cells regained their epithelial phenotype when TbRI-KI was
included in the treatment, suggesting the inhibition of EMT as
indicated by the re-expression of F-actin along cell membrane and
a more even distribution of Snail between cytoplasm and nucleus
(Figure 3C). Our results indicated that TbRI-KI has the potential
to reverse the EMT process by counteracting the action of TGFb
and doxorubicin in inducing EMT in murine breast cancer cells in
vitro.
Doxorubicin or TGFb treatment generated stem cell
phenotype with drug resistance
Recently, EMT has been implicated in the generation of stem
like cells in normal and transformed human mammary epithelial
cells [26,27]. The authors in both studies showed that prolonged
treatment of cells with TGFb1 enhanced expression of markers
associated with EMT and many properties of stem cells which
include expression of cell surface stem cell markers and ability to
form mammospheres. We examined whether murine breast
cancer 4T1 cells, which showed EMT upon treatment with
TGFb1 or doxorubicin, could exhibit stem cell characteristics in
vitro. After 7 days of treatment with either doxorubicin or TGFb1,
the cells were analyzed by flow cytometry for the murine stem/
progenitor cell marker Sca-1 and the multidrug resistance protein
MDR1. A Sca-1 positive population in murine mammary gland
has been shown to be enriched for functional stem/progenitor cells
as demonstrated by its increased regenerative potential in
comparison to the Sca-1 negative cells when transplanted into
the cleared mammary fat pads of host mice [37]. Multi drug
resistance protein has been implicated in cancer stem cell
resistance to chemotherapy [38]. In comparison to the non-
treated cells, the number of cells expressing Sca-1 and MDR1
were enhanced by about 2-fold and 5-fold respectively after
TGFb1 treatment and by about 1.7-fold and 2-fold respectively
after doxorubicin treatment (Figure 4A). The addition of TbR1-
KI during doxorubicin treatment reduced the number of MDR1
expressing cells to the basal level (Figure 4B). Doxorubicin
treatment showed enhanced MDR1 expression in a dose
dependent manner as detected by Western blotting (Figure 4C).
Since TGFb1 treatment increased MDR1 expression in 4T1 cells
which was detected by both flow cytometry (Figure 4A) and
western blotting (Figure 4C), we also tested whether TGFb1
treatment can induce doxorubicin resistance with a cell prolifer-
ation assay. We found that treatment with TGFb1 attenuated
growth inhibitory activity of doxorubicin (Figure 4D), which
indicates that the stem cell phenotype induced by TGFb appears
to enable breast cancer cells to acquire resistance to anti-cancer
agents like doxorubicin. Thus, our results indicated that
doxorubicin or TGFb1 treatment has the potential to generate
drug resistant cancer cells with stem/progenitor cell features.
TbRI-KI reduced doxorubicin-induced mammosphere
formation
One defining characteristic of the stemness of a cell is its ability
to self-renew and to generate differentiated progeny. Recently, a
non-adherent and non-differentiating culture system has been
developed [39] in which a small population of stem like mammary
epithelial cells, capable of surviving anoikis and proliferating in
such conditions, formed discrete clusters of cells termed ‘mammo-
Figure 2. Enhanced phosphorylation of Smad2 and Smad3 in murine and human breast cancer cells by doxorubicin and TGFb
treatment. The murine 4T1 and human MDA-MB-231 breast cancer cells were treated with doxorubicin (25 nM) or TGFb1(2 ng/ml) in the presence
or absence of TGFb antagonist TbRI-KI (500 nM) for 7 days. The medium was changed every alternate day. The cell extracts were used for Western
blotting analysis to measure the levels of phosphorylated Smad2 (P-Smad2) and phosphorylated Smad3 (P-Smad3) with their respective antibodies.
doi:10.1371/journal.pone.0010365.g002
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early progenitor cell which undergoes limited self-renewal and
then gives rise to mammary progenitors capable of multi-lineage
differentiation. It has been shown that mammosphere cultures
from tumor cell lines and human breast metastasis specimens
enrich for tumor initiating cells [40]. Induction of EMT has been
shown to promote mammosphere formation in primary human
mammary epithelial cells after prolonged treatment with TGFb
[26]. We also observed that treatment of 4T1 cells with TGFb1
(0.05 and 0.1 ng/ml) for 12 days stimulated the formation of
mammospheres (Figure S4). We have used this model to study
whether doxorubicin induced EMT can promote the formation of
mammospheres which represents self-renewing stem/early pro-
genitor cells. We found a 5-fold increase in the number of
mammospheres formed by the treatment of 4T1 cells with 25 nM
doxorubicin for 7 days, in comparison to the mammospheres
formed by the non-treated cells. This enhanced formation of
mammospheres by doxorubicin was drastically reduced by the
addition of TbR1-KI (Figure 5A and Figure 5B).
Thus, our in vitro results revealed that the chemotherapeutic
agent doxorubicin can induce TGFb signaling, promote EMT and
generate cells with drug resistant stem cell phenotypes in murine
Figure 3. Inhibition of Doxorubicin- and TGFb-induced EMT by TbRI-KI in murine 4T1 cells. A. Representative pictures of 4T1 cells with
mesenchymal morphology after treatment with TGFb1 (2 ng/ml) or doxorubicin (25 nM) for 7 days (6100 magnification). B. 4T1 cells were treated
with or without TGFb1 (2 ng/ml) or TbRI-KI (500 nM) for 7 days. Cell lysates were analyzed by western blotting with antibody to Vimentin and tubulin.
C. 4T1 cells were treated with TGFb1 (2 ng/ml) or doxorubicin (25 nM) in the presence or absence of TbRI-KI (500 nM) for 7 days. The treated and
non-treated 4T1 cells were harvested and about 4610
3 cells were seeded on a 8-well Lab-Tek chambered coverglass. After 24 hours, the cells were
stained with Rhodamine phalloidin for F-actin or an antibody to Snail. Fluorescent images were taken with a confocal microscope.
doi:10.1371/journal.pone.0010365.g003
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with a TGFb antagonist TbRI-KI. These results prompted us to
test the hypothesis that antagonism of increased TGFb signaling
during doxorubicin treatment in vivo may enhance anti-tumor
activity of doxorubicin in the murine breast cancer 4T1 and
human breast cancer MDA-MB-231 xenograft models.
TbRI-KI enhanced the efficacy of doxorubicin to reduce
tumor growth and spontaneous lung metastasis by
murine breast cancer cells
Balb/c mice were injected with 4T1 cells at both inguinal
mammary glands and treated immediately once a week with a low
or a high dose of doxorubicin (4 mg and 8 mg/kg body weight), or
with TbRI-KI (1 mg/kg body weight) every alternate day, either
alone or in combination, by i.p. injection. Treatment with TbRI-
KI for 21 days moderately inhibited primary tumor growth of 4T1
tumors while treatment with doxorubicin induced a dose-
dependent and more noticeable inhibition in comparison to the
placebo treatment (Figure 6A). However, much more significant
inhibition of tumor growth was obtained when the treatment of
TbRI-KI was combined with doxorubicin at both low (DOXO-4)
and high doses (DOXO-8) (Figure 6A). In fact, the combination of
TbRI-KI and the low dose of doxorubicin produced a similar
inhibitory effect to that of the high dose of doxorubicin alone.
After the termination of the experiment, metastatic tumor nodules
on the surface of the lungs, as shown in Figure 6B, were counted.
The metastatic burden on the lungs, as represented by the number
of tumor nodules, was moderately, but dose dependently, lowered
by doxorubicin treatments. Interestingly, while TbRI-KI was not
as effective as doxorubicin in inhibiting orthotopic tumor growth,
it was much more effective in blocking lung metastasis than
doxorubicin suggesting that metastasis can be independent of
primary tumor size (Figure 6C). The combination between TbRI-
KI and the higher dose of doxorubicin produced greater inhibition
of lung metastasis than either treatment alone (Figure 6C). Thus,
combination treatment of doxorubicin and TbRI-KI effectively
enhanced the inhibition of both tumor growth and spontaneous
lung metastasis of murine 4T1 cells in comparison to the single
treatments.
TbRI-KI inhibited doxorubicin-induced spontaneous lung
metastasis of human breast cancer cells
We also utilized the human breast cancer MDA-MB-231 cells
expressing enhanced green fluorescence protein (EGFP) to
investigate the effects of doxorubicin and/or the TGFb antagonist
TbRI-KI treatment on metastasis induced by orthotopic xenograft
tumors formed by the MDA-MB-231 cells. The treatment was
initiated when the average tumor volume was between 80–
100 mm
3. After 21 days of treatment with both i.v. injection of
doxorubicin (4 mg/kg/wk) and i.p. injection of the TbRI-KI
(1 mg/kg/2days), either alone or in combination, we examined
the tumor growth rate and the spontaneous lung metastasis.
Similar to the 4T1 tumor model, combination treatment
significantly reduced tumor growth in comparison to the single
treatments although treatment was started after the initiation of
tumor growth (Figure 7A). Most interestingly, examination of the
whole lungs revealed that the size of the metastatic colonies was
much larger in doxorubicin group than in the control group as
observed by EGFP fluorescence imaging (Figure 7B). Further-
more, there was increased number of mice with greater than 50
lung metastatic colonies in the doxorubicin-treated group in
comparison to the control group (Figure 7C) even though
doxorubicin treatment moderately reduced primary tumor growth
(Figure 7A) indicating that doxorubicin alone can stimulate
Figure 4. Doxorubicin and TGFb treatment generated drug resistant cells with a stem cell phenotype. A and B. The murine 4T1 breast
cancer cells were treated with TGFb1 (2 ng/ml) or doxorubicin (25 nM) in the presence or absence of TbRI-KI (500 nM) for 7 days. The medium was
changed every alternate day. The treated and non-treated cells were harvested with trypsinization and incubated with an alexafluor 405-conjugated
antibody (2 mg/10
6 cells) against MDR1 or a Phycoerythrin-conjugated antibody against Sca-1. Fluorescence Activated Cell Sorting (FACS) analysis
was carried out using FACSAria flow cytometer (Becton Dickinson). Results were expressed as fold increase of the number of cells expressing the
surface markers for Sca-1 or MDR1 after treatment with TGFb1 or doxorubicin compared to the untreated cells (A) or as the percentage of MDR1
expressing cells after doxorubicin treatment in the presence or absence of TbR1-KI (B). C. 4T1 cells were treated with or without 2 ng/ml TGFb1 and
DOXO (10 nM and 25 nM) for 7 days and cell extracts were used for Western blot analysis with antibody to MDR1. D. 4T1 cells, pre-treated with
TGFb1 (5 ng/ml) for seven days, were plated in a 96-well plate and were treated with doxorubicin at two different concentrations (1 nM and 10 nM)
in the presence or absence of TGFb1 (5 ng/ml). Relative cell number after 5 days of incubation was obtained by MTT assay. Each data point is the
mean6SEM from 4 replicate wells.
doi:10.1371/journal.pone.0010365.g004
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tumor growth, however a statistically significant reduction of
tumor volume was only observed with the treatment of both
doxorubicin and TbRI-KI in comparison to that of the control
group (Figure 7A). More significantly, the combination treatment
remarkably inhibited lung metastasis as evidenced by reduced lung
metastatic colonies both in colony size (Figure 7B) and number
(Figure 7C9). The size of lung metastatic colonies in TbRI-KI
group was similar to that in the combination treatment group
(picture not shown). The fact that the number of mice with 1–20
lung metastases in the combination treatment group was still
higher than that in TbRI-KI alone group suggests that TbRI-KI
treatment did not completely inhibit doxorubicin-induced lung
metastasis. Thus, our study indicates that the TGFb inhibitor has
the potential to inhibit doxorubicin-induced lung metastasis.
TbRI-KI reduced doxorubicin-induced spontaneous bone
metastasis in a murine xenograft model
Breast cancer metastasizes to multiple sites and frequently to the
skeleton, resulting in poor prognosis. In our previous study we
found that systemic administration of the TbRI-KI can inhibit
bone metastasis of human cancer cells in an intra-cardiac injection
model of bone metastasis [22]. Orthotopic tumors formed by 4T1
cells have been shown to induce spontaneous bone metastasis [41].
However, we failed to detect tumor cells in the sections of femora
and tibiae from either the control or the treated mice in our
experiment described in Figure 6. We suspected that the
experiment duration of three weeks might not be long enough
for metastatic 4T1 cells to form tumors in bony tissue. Therefore,
we performed another set of experiment with the 4T1 cells, in
which the treatment with doxorubicin and/or TbRI-KI was
Figure 5. Abrogation of doxorubicin induced mammosphere formation by TbRI-KI. Murine 4T1 cells were treated with doxorubicin
(25 nM) in the presence or absence of TbRI-KI for 6 days. The cells with or without treatment were harvested after trypsinization and filtered through
40 mm strainer to obtain a single-cell suspension. Cells were seeded (1,000 cells/100 ml/well) in a 96-well ultra-low attachment plate (Costar) and
mammospheres were counted after 7 days of incubation. A. Representative pictures of mammospheres obtained from cells with or without
doxorubicin treatment and also after doxorubicin treatment in the presence of TbRI-KI. B. The number of mammospheres obtained from 1,000 cells
in triplicate wells with or without treatments were counted and expressed as mean6SEM. ‘‘*’’ indicates significant difference from the control value,
P,0.05.
doi:10.1371/journal.pone.0010365.g005
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size of 60–70 mm
3. Doxorubicin was administered by i.v. injection
and TbRI-KI by i.p. injection for 21 days. This combination
treatment inhibited the tumor growth in comparison to the single
treatments (Figure 8A). Tibia specimens in all treatment groups
were analyzed for the incidence of bone metastasis, tumor burden
and osteolysis indicated by the loss of trabecular bone after
histological staining. Metastatic 4T1 tumors in different specimens
were seen at different areas of tibia, often away from the trabecular
bone area. Therefore, osteolysis as reflected by loss of trabecular
bone could not be compared between the placebo and the treated
mice with bone metastasis. More metastatic tumors in the tibia
were seen after single treatment with either dose of doxorubicin
than treatment with TbRI-KI, which moderately reduced the
incidence of metastasis in comparison to the placebo treatment
group (Figure 8B). More significantly, the metastasis incidence was
reduced by 50–60% when animals were treated with both
doxorubicin and TbRI-KI (Figure 8B). We also compared the
percent incidence of different levels of the tibial tumor burden
among the treatment groups. We recorded the levels of tumor
burden as: no bone metastasis, ,20% tibia replaced by tumor,
20–50% tibia replaced by tumor, and .50% of tibia replaced by
tumor. The percentage of specimens with higher tumor burden
(.50%) was evident only in the placebo or doxorubicin-treated
groups but not in the TbRI-KI-treated or the combination
treatment groups (Figure 8C). About 70% animals were free of
bone metastasis after the combination treatment in comparison to
about 24% and 32% in the low and high dose doxorubicin
treatment group respectively (Figure 8C). These results demon-
strated that doxorubicin treatment alone increased the bone
metastasis incidence and bone tumor burden which were
remarkably reduced by the simultaneous treatment with a TGFb
inhibitor.
Although the combination treatment after tumors were formed
and growing was effective in inhibiting bone metastasis, its effect
on lung metastasis was much less obvious because the majority of
lungs in each treatment group were covered with metastatic
nodules making it difficult to count the nodules. Thus, our results
indicate that early treatment with the combination of doxorubicin
and TbRI-KI will likely be much more effective than delayed
treatment in blocking lung metastasis.
Discussion
In this study, we have evaluated the potential therapeutic
benefit of using a small molecule TGFb signaling inhibitor with
doxorubicin in animal models of breast cancer. Doxorubicin,
which is a frequently used chemotherapeutic agent against
metastatic breast cancer, has been reported to induce acute and
chronic toxicities and immunosuppression. In addition, we found
in our study that doxorubicin can activate TGFb signaling in
cancer cells, which has the potential to accelerate malignant tumor
progression. Thus, novel treatment options are needed to reduce
dosages of doxorubicin and consequently unwanted toxicities
while enhancing its therapeutic efficacy in treating metastatic
cancer.
An elevated plasma level of TGFb has been correlated to the
progression of various types of malignancies including metastatic
breast cancer progression [9] and survival [42]. Persistent high
levels of circulating TGFb predicted early metastatic recurrences
in the liver of patients with colorectal cancer after curative
resection [43]. In addition to the carcinogenesis-associated
Figure 6. TGFb inhibitor enhances the efficacy of doxorubicin treatment to reduce tumor growth and spontaneous lung metastasis
of murine breast cancer cells. A. Murine breast cancer 4T1 cells (0.1610
6) were inoculated at the both inguinal mammary fat pad of syngeneic
Balb/c mice and divided into six groups. Animals were treated with PBS (Placebo), TbRI-KI at 1 mg/kg every alternative day, doxorubicin (DOXO) at
4 mg/kg (DOXO-4) or 8 mg/kg (DOXO-8) once per 7 days, or the combination of TbRI-KI and DOXO-4 or DOXO-8 through i.v. injection starting at the
day of tumor cell inoculation. Tumor sizes were measured twice weekly with a caliper, and the tumor volumes were calculated with the equation
V=(L 6W
2)60.5, where L is length and W is width of a tumor. Experiment was terminated after 3 wks of treatment and the final tumor volume (sum
of two tumors per mouse) was used for calculating mean tumor volume 6 SEM from 6 mice in Placebo and 5 mice in the rest of the groups. B and C.
After the termination of the experiment, lungs were excised and fixed in Bouin’s solution (Sigma) to count surface lung metastasis, followed by
paraffin embedding for histological H & E staining. Representative picture of lungs without and with metastatic nodules are shown with
corresponding histological identification of the nodules by H & E staining (B). The visible surface lung nodules were counted. ‘‘*’’ denotes a significant
difference (P,0.005) from the corresponding control with a Student t test (C).
doi:10.1371/journal.pone.0010365.g006
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agents including doxorubicin were shown to stimulate TGFb1
expression and secretion from xenograft tumors [31]. Surprisingly,
in a recent study, it was shown that doxorubicin treatment caused
increased circulating levels of TGFb as well as increased
circulating tumor cells and lung metastases in the MMTV/
PyVmT transgenic animal model [32]. We have observed that the
presence of doxorubicin induced the migration and invasion of
murine 4T1 and human MDA-MB-231 breast cancer cells similar
to the TGFb1 treated cells in a Boyden chamber assay. Further
investigation revealed that doxorubicin stimulated the phosphor-
ylation of Smad2 and Smad3 in both 4T1 and MDA-MB-231
cells. Consistent with the stimulation of Smad2 and Smad3
phosphorylation, doxorubicin also stimulated the TGFb-respon-
sive PAI-1 promoter activity in a dose dependent manner. Our
results strongly indicate that although doxorubicin can induce
cytostatic and/or cytocidal effects, it can also induce cancer cell
migration/invasion by activating TGFb pathway.
EMT is a latent embryonic program by which some cells within
a tumor during cancer progression can reactivate mesenchymal
traits to disseminate to metastatic sites [33]. Induction of EMT by
TGFb has been shown to increase motility and invasiveness via the
disassembly of cell-to-cell contacts, loss of cell polarity and
significant cytoskeletal reorganization in normal and malignant
mammary epithelial cell types. We observed in the murine breast
cancer 4T1 cell model that TGFb and surprisingly also
doxorubicin can induce EMT as evidenced by the mesenchymal
morphology, reorganization of the actin cytoskeleton and nuclear
localization of the embryonic transcription factor Snail.
Emerging evidence has shown that certain type of tumors
including breast tumors contain a subset of cells that initiate and
propagate the tumors with high efficiency. These cells are
Figure 7. Treatment with TbRI-KI blocked doxorubicin-induced spontaneous lung metastasis of human breast cancer cells. A. EGFP-
expressing sub confluent MDA-MB-231 cells (1610
6) were inoculated into both inguinal mammary fat pads of female athymic nude mice. Tumor
volume was measured externally and calculated as described in the legend of Figure 5. Tumors were allowed to reach 80–100 mm
3 in size and the
animals were then ranked according to their tumor burden and divided into four groups such that the mean and the median of the tumor volume of
the groups are closely matched. Animals were treated with PBS (control), TbRI-KI every alternative day, doxorubicin once every week, and with the
combination of TbRI-KI and doxorubicin respectively. The experiment was terminated after 3 weeks and the final tumor volume (sum of two tumors
per mouse) was used for calculating mean tumor volume6SEM from 4 mice in control and TbRI-KI groups and 5 mice in the other two groups.
Asterisk ‘‘*’’ denotes significant difference (P,0.05) of the terminal tumor volumes between control and the combination treatment group by
ANOVA. B. Representative Pictures of lung metastasis colonies formed by EGFP-expressing MDA-MB-231 cells detected by fluorescence microscopy
(6200 magnification). C. Green fluorescent micrometastatic colonies in the whole lung were detected and counted. The percent of mice with lung
metastasis in each group is expressed as total lung metastasis incidence. Incidence as percent of mice with numbers of lung metastasis colonies
ranging between 1 and 20, between 20 and 50, and .50 is also presented.
doi:10.1371/journal.pone.0010365.g007
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resembling normal stem cell properties such as expression of
stem cell markers, self renewal and multipotency [44]. Metastatic
breast cancer cells are notorious for their ability to survive
treatment and regenerate tumors. One important feature of
CSCs is their resistance to the cytotoxicity of varous chemo-
therapeutic agents because of their relatively high expression
levels of multiple drug resistance transporters such as ABCB1
(MDR1/PGP, P-glycoprotein) and ABCG2 (MXR/BCRP) [38].
Thus, chemotherapeutics might spare CSC’s and allow recur-
rence of more aggressive tumors. Recent data showed that
immortalized human and murine breast cancer cell lines contain
stem-like cells similar to CSCs isolated from primary tumor
tissue with identical cell surface markers, clonogenic and sphere
formation potential, and in vivo functional transplantation
properties [45]. The fact that EMT can generate stem-like
cancer cells [26] suggests that therapeutic-resistant cancer stem
cells may be the result of either the transformation of normal
stem cells or via the induction of EMT in more differentiated
cancer cells. Indeed, we found that treatment with TGFb or
doxorubicin increased the number of 4T1 cells expressing stem
cell marker Sca-1 and the drug resistant transporter protein
MDR1, and with the stem cell property of self-renewal as
indicated by mammosphere formation. The 4T1 cells pre-treated
with TGFb1 for 7 days showed resistance to the doxorubicin-
induced growth inhibition.
Our results indicate that by activating TGFb signaling,
doxorubicin has the ability to induce EMT and generate tumor
cells with stem cell phenotypes. The EMT program is often
considered a transient and reversible process. Studies of embryonic
development have showed that mesenchymal cells of mesoderm
can give rise to epithelial organs, including the kidney and ovary,
by undergoing the reverse EMT [46]. The finding that EMT plays
a role in the development of cancer stem cells suggests that
therapies blocking or reversing the EMT program may sensitize
resistant cancer stem cells to conventional cancer therapies. We
have evaluated the ability of a small molecule TGFb inhibitor,
TbRI-KI, to block the EMT process and subsequent cancer stem
cell formation by TGFb1 and doxorubicin treatment in 4T1 cells
in vitro. We found that blockade of TGFb signaling significantly
reversed the TGFb1- and doxorubicin-mediated EMT process.
Restoration of the epithelial phenotypes of the cytoskeleton
organization and cytoplasmic localization of the EMT transcrip-
tion factor Snail was observed in the presence of the inhibitor. The
treatment of TbRI-KI also inhibited TGFb1- and doxorubicin-
mediated generation of cells with stem cell phenotypes including
the expression of MDR1 and the formation of mammospheres.
Thus, all our in vitro experiments indicated potential therapeu-
tic benefits of using TbRI-KI to antagonize the doxorubicin-
induced TGFb signaling, which has the potential to induce EMT
and to generate drug resistant stem-like cancer cells. We designed
in vivo experiments utilizing murine breast cancer 4T1 cells and
human breast cancer MDA-MB-231 cells to study the synergistic
anti-tumor effect of the systemic administration of both doxoru-
bicin and TbRI-KI in comparison to single-agent treatments. Our
studies revealed that while treatment with either agent alone
moderately inhibited tumor growth in both xenograft breast
cancer models, the combination of both agents was clearly much
more effective in inhibiting tumor growth. In fact, a 50%
reduction of doxorubicin dose was sufficient to produce the same
tumor growth inhibition as the full dose when TbRI-KI was added
to the treatment suggesting that the combination with TGFb
antagonists may be an effective strategy in reducing doxorubicin
dosage and its unwanted side-effects.
Figure 8. TbRI-KI reduced doxorubicin-induced spontaneous bone metastasis in the murine xenograft model. A. 4T1 cells (0.1610
6)
were inoculated into both inguinal mammary fat pads of syngeneic female balb/c mice. When the average tumor volume reached 60–70 mm
3 after 2
weeks, the mice were divided into six groups with similar tumor burden and treated i.p. with PBS (control), TbRI-KI at 1 mg/kg every alternative day,
doxorubicin at 4 mg/kg (DOXO-4) or 8 mg/kg (DOXO-8) once per 7 days, or the combination of TbRI-KI and DOXO-4 or DOXO-8. The experiment was
terminated after 3 wks of treatment and the final tumor volume (sum of two tumors per mouse) was used for calculating mean tumor volume6SEM
from 6 mice in DOXO-8 and 5 mice in the rest groups. The bars bearing a different letter are significantly different (P,0.05) by ANOVA. B. After the
termination of the experiment, the leg bones (Femora and tibiae) were fixed in 10% neutral buffered formalin, decalcified in 10% EDTA and
embedded in paraffin. Sections were stained with H&E, orange G and phloxine. The presence of tumors in the bone marrow was examined
microscopically. The incidence of bone metastasis in each group of animals was expressed in percentage of the number of animals with bone
metastasis. C. Animals with bone tumor burden were divided into four groups and the results were expressed in percentage of animals with no bone
metastasis, with ,20% tibia replaced by tumor, with 20–50% tibia replaced by tumor, and with .50% of tibia replaced by tumor.
doi:10.1371/journal.pone.0010365.g008
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breast cancer [47]. About 60% to 74% of patients who die of
breast carcinoma have lung metastasis [48]. In several animal
models, TGFb has been shown to promote lung metastasis
[49,50]. Since Doxorubicin is widely used as an adjuvant
chemotherapeutic agent in metastatic breast cancer with limited
response rate (4) and enhanced lung metastasis in an animal model
[32], we also examined the lungs of the animals for the presence of
metastatic colonies in the placebo and treatment groups. We
observed moderate reduction of lung metastasis after doxorubicin
treatment which was significantly improved by combinational
therapy with TbRI-KI in the murine 4T1 xenograft model. In the
human breast cancer xenograft model, our results indicated that
doxorubicin alone can stimulate lung metastasis with larger
metastatic colonies which can be effectively blocked by the
simultaneous treatment with TbRI-KI. Since smaller sized
pulmonary metastasis has been shown to be significantly associated
with longer survival [47], our results suggest that administration of
TbRI-KI along with doxorubicin may have the potential to
improve the survival rate of doxorubicin-treated metastatic breast
cancer patients.
Metastases to bone are frequently seen pathological lesions in
advanced breast cancer, which causes debilitating skeletal
complications such as osteolysis, intractable bone pain and
pathologic fractures [51]. Most importantly, once breast tumor
cells metastasize to bone marrow, mortality increases to 70% in
comparison to 40% in the breast cancer patients with no tumor
cells in their bone marrow [52,53]. Therefore, prevention and
treatment of bone metastasis is important for the improvement of
survival in breast cancer patients. In our study, we observed that
mice bearing orthotopic 4T1 tumors showed an increased
incidence of spontaneous bone metastasis as well as greater bone
tumor burden after doxorubicin treatment in comparison to the
placebo treatment. Both incidence of tumor cells and tumor
volume in the bone marrow were reduced remarkably after
simultaneous treatment with TbRI-KI even though TbRI-KI
treatment alone was only moderately effective in reducing bone
metastasis incidence and tumor burden. Thus, the combination
therapy appears to produce a synergistic inhibition of bone
metastasis in this model system.
In summary, our study suggests that doxorubicin at certain
dosages can promote breast cancer invasion and metastasis in part
through its ability to activate TGFb signaling, which in turn
generates stem-like cancer cells with increased drug resistance
through an EMT process. Our study also suggests that
administration of TGFb antagonists during chemotherapy may
sensitize carcinoma cells, in part through the inhibition of EMT, to
the anti-tumor and anti-metastatic activities of chemotherapy
resulting in increased therapeutic efficacy and reduced dosage of
chemotherapeutics and their unwanted side effects.
Materials and Methods
Ethics statement
All animal experiments were conducted following appropriate
guidelines. They were approved by the Institutional Animal Care
and Use Committee and monitored by the Department of
Laboratory Animal Resources at the University of Texas Health
Science Center at San Antonio.
Cell lines
Human breast cancer cell line MDA-MB-231 and murine
breast cancer 4T1 cell line was originally obtained from the
American Type Tissue Culture Collection (ATCC). These cell
lines were cultured in McCoy’s 5A medium supplemented with
pyruvate, vitamins, amino acids, antibiotics, and 10% fetal bovine
serum (FBS) as described previously [54].
Western Blotting
The murine 4T1 and human MDA-MB-231 breast cancer cells
were treated with doxorubicin (25 nM) in the presence or absence
of TGFb1 (2 ng/ml) and/or TbRI-KI (500 nM) for 7 days. The
medium was changed every alternate day with the addition of
doxorubicin and TGFb1 each time. The cell lysates were used in
the western blotting analysis as described previously [14].
Antibody to the Phospho-Smad2 was from Cell signaling, to
vimentin was from Sigma, and to Phospho-Smad3 and MDR1
was from Santa Cruz Biotechnology. The TbRI-KI used in our
study was previously reported to be an ATP competitive inhibitor
of the TGFb RI kinase [55,56]. The compound, [3-(pyridine-2yl)-
4-(4-quinonyl)]-1H pyrazole, was synthesized according to the
procedure described by Sawyer et al. [55].
In vitro cell migration and invasion assays
Cell migration and invasion assays were performed in 24-well
Boyden Chambers with 8-mm pore polycarbonate membranes
(Becton Dickinson Labware, Rockville, MD) for migration assays
and with matrigel coated membranes for invasion assay. For
migration assay, 40,000 murine breast cancer 4T1 cells and
human breast cancer MDA-MB-231 cells in serum free medium
were seeded in the upper chamber and treated with doxorubicin
(100 nM) or TGFb1 (5 ng/ml) and incubated for 6 hours and
24 hours respectively. Lower chamber contained the medium with
1% serum as chemoattractant. After incubation, cells were
removed from the upper surface of the chamber membrane with
a cotton swab and the membrane was then stained for the
migratory cells at the lower surface of the chamber with Hema 3
stain kit (Fisher Scientific, Houston, TX) according to the
manufacturer’s protocol. The stained cells were counted under a
microscope. For invasion assay using matrigel coated chambers,
50,000 murine 4T1 cells and human MDA-MB-231 cells in serum
free medium were used and treated similarly as described above
with doxorubicin or TGFb1 for 18 hours and 24 hours respec-
tively. Lower chamber contained the complete medium with 10%
serum as chemoattractant. Invasive cells were stained and counted
as described above.
Mammosphere culture
Murine 4T1 cells were treated with doxorubicin (25 nM) for 6
days in the presence or absence of TbRI-KI (500 nM). The
medium with doxorubicin was changed every alternate day. The
cells with and without treatment were harvested after trypsiniza-
tion with 0.05% trypsin and filtered through a 40-mm strainer to
obtain a single-cell suspension. Cells were seeded (1000 cells/
100 ul/well) in a 96 well ultra-low attachment plate (Costar) in
DMEM-F12 medium supplemented with 2% B27 (Gibco), which
is a serum replacement that excludes constituents that lead to cell
differentiation and 20 ng/ml EGF, 20 ng/ml bFGF, 0.5 mg/ml
hydrocortisone, 5 mg/ml insulin and gentamycin/amphotericin-B
(Lonza). Mammospheres were counted after 5–7 days of
incubation.
Flow Cytometry
The murine 4T1 breast cancer cells were treated with
doxorubicin (25 nM) in the presence or absence of TGFb1
(2 ng/ml) and/or TbRI-KI (500 nM) for 7 days. The medium was
changed every alternate day with the addition of doxorubicin and
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after trypsinization were stained for flow cytometry at a
concentration of 1610
6 cells per 100 ml of buffer (PBS pH 7.4,
2% PBS, 2 mM EDTA). Cells were incubated with conjugated
antibodies (2 mg/10
6 cells) against MDR (Anti MDR-alexafluor
405, Santa Cruz Biotechnology) and Sca-1 (anti Sca-1-PE, BD
Biosciences) at 4uC for 20 min. Fluorescence activated cell sorting
(FACS) analysis was carried out using FACSAria flow cytometer
(Becton Dickinson) at the core imaging facility of the UT Health
Science Center at San Antonio, Texas.
Cell proliferation assay
4T1 cells pre-treated with TGFb1 for seven days were plated in
a 96-well plate at 2,000 cells/well. Cells were treated with
doxorubicin at two different concentrations (1 nM and 10 nM) in
the presence or absence of TGFb1 (5 ng/ml) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
was utilized to obtain the relative cell number after 5 days of
incubation as described previously [22].
Immunofluorescence
The treated and non-treated cells (as described earlier) were
harvested and about 4610
3 cells were seeded on a 8-well Lab-Tek
chambered coverglass (Nunc International, Rochester, NY) and
stained with Rhodamine phalloidin (Molecular probes) for F-actin
or antibodies to Snail (Cell Signaling) after 24 hours. Briefly, for F-
actin staining, cells were fixed in 4% paraformaldehyde,
permeabilized in 0.1% Triton-X100 and incubated with Rhoda-
mine phalloidine (1:100 dilution) for 30 min. For the staining with
Snail antibody, cells were fixed in 4% paraformaldehyde for
15 min, incubated with 5% normal goat serum in PBS/Triton-
X100 for 60 min, with primary antibody at 4uC overnight, and in
Alexafluor 568 fluochrome-conjugated secondary antibody for
1 hr at room temperature. The slides were mounted with
vectashield mounting media (Vector) and viewed under an
Olympus Fluoview FV1000 confocal fluorescence microscope.
Animal Studies
Four-week-old female BALB/c and athymic nude mice
(obtained from Harlan Sprague Dawley, Inc. Indianapolis, IN)
were used for in vivo animal experiments. The animals were housed
under specific pathogen free conditions. We investigated the effects
of doxorubicin and/or TbRI-KI treatment on orthotopic
xenograft tumors formed by murine 4T1 or human MDA-MB-
231 breast cancer cell lines, and also on their subsequent
spontaneous lung and/or bone metastasis. Murine breast cancer
4T1 cells (0.1610
6) and human breast cancer EGFP expressing
MDA-MB-231 cells (1.0610
6) were inoculated at the both inguinal
mammary fat pad of syngeneic BALB/c mice and athymic nude
mice respectively. In the study with 4T1 xenograft model, animals
were treated with Doxorubicin (once a week via intraperitoneal
(i.p.) or intravenous (i.v.) injection in two doses of 4 mg/kg and
8 mg/kg animal body weight respectively) and TbRI-KI (every
alternative day via i.p. injection of 1 mg/kg body wt) either alone
or in combination in two sets of experiment. In the first
experiment, treatment started immediately after tumor cell
inoculation and in the second experiment, treatment started when
the average tumor volume per mouse was between 60–70 mm
3.I n
the study with MDA-MB-231 cells, treatment of doxorubicin and
TbR1-KI with similar doses as described above was started when
the average tumor volume was between 80–100 mm
3/mouse.
Placebo control group received PBS every alternate day. In both
studies, animals were ranked in closely matched groups according
to their tumor volumes. Tumor sizes were measured twice weekly
with a caliper, and the tumor volumes were calculated with the
equation V=(L6W
2)60.5, where L is length and W is width of a
tumor. In all studies, animals were sacrificed after 21 days of
treatment.
In vivo spontaneous lung and bone metastasis assay
After the termination of the all in vivo experiments, lungs were
excised and metastatic cancer cell colonies were visually observed.
In the 4T1 study, lungs were fixed in Bouin’s solution (Sigma) and
surface lung nodules were counted. In the MDA-MB-231 study,
EGFP expressing green lung metastatic colonies were observed
and counted under a fluorescence microscope followed by 10%
buffered formalin fixation. All lung specimens were embedded in
paraffin and stained with hematoxylene and eosin. To analyze
spontaneous bone metastasis in the 4T1 model, bone tissues (tibia
and femora) were fixed in 10% neutral buffered formalin (Fisher
Scientific) for 48 hours at room temperature, decalcified in 10%
EDTA and embedded in paraffin. Sections were stained with
hematoxylin, eosin, orange G and phloxine. The tumor burden in
femora and tibia was examined microscopically.
Statistical analysis
Student t tests were used for the comparison between two mean
values. For the comparison of more than two mean values we used
one-way analysis of variance (ANOVA) followed with Newman-
Keuls Multiple Comparison Test. All statistical analysis was
performed using Prism version 3.03 software (GraphPad Software
Inc.).
Supporting Information
Figure S1 TGFb and doxorubicin stimulated invasion of murine
and human breast cancer cells. In a Boyden chamber invasion
assay, 50,000 murine breast cancer 4T1 cells (A) and human
breast cancer MDA-MB-231 cells (B) in serum free medium were
placed inside the insert of an invasion chamber coated with
matrigel and treated with doxorubicin (100 nM) or TGFb1 (5 ng/
ml in A and 1 ng/ml in B) for 18 hours and 24 hours respectively.
Lower chamber contained the complete medium with 10% serum
as chemoattractant. Stained membranes were counted under a
microscope. Results are the mean+SEM of invasive cell numbers
in three fields of observation at 1006magnification in A and total
number of invasive cells in B.
Found at: doi:10.1371/journal.pone.0010365.s001 (0.09 MB
TIF)
Figure S2 Doxorubicin treatment enhanced TGFb signaling in
murine and human breast cancer cells. A. The murine 4T1 and
human MDA-MB-231 breast cancer cells were treated with
doxorubicin (25 nM) or TGFb1 (2 ng/ml) in the presence or
absence of TGFb antagonist TbRI-KI (500 nM) for 24 hours. The
cell extracts were used for Western blotting analysis to measure the
levels of phosphorylated Smad3 (P-Smad3). B. Mink lung
epithelial cells stably transfected with TGFb-responsive PAI-1
promoter-luciferase reporter construct were plated in a 96-well
plate and treated with doxorubicin or TGFb1 (0.5 ng/ml) for
24 hr. Luciferase activity was measured in cell lysate. Data are
mean6SEM of 3 wells.
Found at: doi:10.1371/journal.pone.0010365.s002 (0.09 MB TIF)
Figure S3 Doxorubicin induced EMT in human breast cancer
MDA-MB-231 cells. MDA-MB-231 cells were treated with
TGFb1 (2 ng/ml) or doxorubicin (25 nM) in the presence or
absence of TbRI-KI (500 nM) for 7 days in an 8-well Lab-Tek
chambered coverglass (Nunc International, Rochester, NY). Cells
Doxorubicin and TGFb Inhibitor
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F-actin cytoskeleton was viewed under an Olympus Fluoview
FV1000 confocal fluorescence microscope.
Found at: doi:10.1371/journal.pone.0010365.s003 (0.28 MB TIF)
Figure S4 Prolonged treatment of 4T1 cells with TGFb1
enhanced formation of mammospheres. 4T1 cells were treated
with 0.05 or 0.1 ng/ml of TGFb1 for 12 days with medium
change every alternate day. Cells were harvested and passed
through a 40 mm nylon membrane to obtain a single cell
suspension. Cells were plated (2,000 cells per well) in a 24-well
ultra low attachment plate in DMEM-F12 mammosphere culture
medium. The number of large mammospheres (.100 mmi n
diameter) obtained from 2,000 cells with or without TGFb1
treatment were counted and presented in Panel A. The
representative photos of mammosphere are shown in Panel B.
Found at: doi:10.1371/journal.pone.0010365.s004 (0.10 MB TIF)
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